Fig. 6 | Nature Communications

Fig. 6

From: Smac mimetics and oncolytic viruses synergize in driving anticancer T-cell responses through complementary mechanisms

Fig. 6

LCL161 and VSVΔM51 combination therapy synergizes with αPD-1 therapy. a Overall survival of EMT6 tumor-bearing mice treated with LCL161 + VSVΔM51 ± PD-1 antibody (or isotype control; duplicate experiments; log-rank test). b PD-L1 expression on EMT6 cells treated for 24 h with IFNγ (or vehicle) at the indicated concentrations, measured by flow cytometry (n = 3 biological replicates, single experiment). c PD-L1 expression on the indicated populations of cells isolated from 12-day-old EMT6 tumors (single experiment; mean ± SD). d, e Membrane staining for PD-1 and Tim-3 expression on CD8+ and CD4+ T cells isolated from EMT6 tumors d and TdLN e 7 days post treatment, measured by flow cytometry (duplicate experiments; mean ± SD; t-test). f PD-L1 expression on the indicated populations of TAM isolated from EMT6 tumors 72 h post TX (single experiment; mean ± SD; t-test)

Back to article page